This is the authors' abstract. We don't add key points for this paper.
New triazole‐imidazole and tetrazole‐imidazole hybrids were obtained using 2,4,5‐triaryl‐1‐(4‐aminophenyl) imidazoles by copper‐catalyzedazide‐alkyne cycloaddition (CuAAC) and Ugi‐azidefour‐component(UA‐4CRs) process. The synthesis of triazole hybrids was performed in the presence of new copper‐incorporated white sandstone nanocatalyst, which was fully characterized by different methods. The construction of newly prepared hybrids was confirmed by spectroscopic techniques. Some of these compounds were evaluated for their anti‐cancer properties against MCF‐7 cancer cell lines. The absorption and emission parameters of the triazole‐ and tetrazole‐substituted imidazoles were also investigated and compared with each other.
No takes yet. Share an insight, caveat, or question.
Fakhree et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: